Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

laboratorios farmacéuticos rovi, s.a. - risperidone - skisofreenia - psühhoeptikumid - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Eesti - eesti - Ravimiamet

norameda uab - nintedaniib - pehmekapsel - 100mg 60tk

Eesti - eesti - Ravimiamet

laboratorios liconsa s.a. - ibandroonhape - õhukese polümeerikattega tablett - 150mg 3tk; 150mg 1tk

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - olmesartaanmedoksomiil+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 20mg+5mg+12,5mg 28tk; 20mg+5mg+12,5mg 300tk; 20mg+5mg+12,5mg 500tk; 20mg+5mg+12,5mg 280tk; 20mg+5mg+12,5mg 56tk; 20mg+5mg+12,5mg 98tk; 20mg+5mg+12,5mg 30tk; 20mg+5mg+12,5mg 90tk; 20mg+5mg+12,5mg 7tk; 20mg+5mg+12,5mg 10tk; 20mg+5mg+12,5mg 84tk

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - olmesartaanmedoksomiil+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 40mg+5mg+12,5mg 280tk; 40mg+5mg+12,5mg 56tk; 40mg+5mg+12,5mg 500tk; 40mg+5mg+12,5mg 50tk; 40mg+5mg+12,5mg 10tk; 40mg+5mg+12,5mg 30tk; 40mg+5mg+12,5mg 14tk

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - olmesartaanmedoksomiil+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 40mg+10mg+25mg 28tk; 40mg+10mg+25mg 10tk; 40mg+10mg+25mg 98tk; 40mg+10mg+25mg 50tk; 40mg+10mg+25mg 280tk; 40mg+10mg+25mg 7tk; 40mg+10mg+25mg 90tk; 40mg+10mg+25mg 500tk

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - olmesartaanmedoksomiil+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 40mg+5mg+25mg 90tk; 40mg+5mg+25mg 50tk; 40mg+5mg+25mg 56tk; 40mg+5mg+25mg 28tk; 40mg+5mg+25mg 7tk; 40mg+5mg+25mg 84tk; 40mg+5mg+25mg 14tk; 40mg+5mg+25mg 300tk; 40mg+5mg+25mg 98tk; 40mg+5mg+25mg 500tk

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - olmesartaanmedoksomiil+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 40mg+10mg+12,5mg 300tk; 40mg+10mg+12,5mg 90tk; 40mg+10mg+12,5mg 7tk; 40mg+10mg+12,5mg 28tk; 40mg+10mg+12,5mg 84tk; 40mg+10mg+12,5mg 14tk; 40mg+10mg+12,5mg 98tk; 40mg+10mg+12,5mg 500tk; 40mg+10mg+12,5mg 30tk; 40mg+10mg+12,5mg 280tk; 40mg+10mg+12,5mg 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - mitu müeloomit - antineoplastilised ained - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.